Anupam Rasayan India to Acquire 26% Stake in Bliss GVS Pharma via Open Offer
Anupam Rasayan India Limited is making an open offer to acquire 26% of Bliss GVS Pharma's shares at ₹299 per share, totaling ₹829.03 crore. This follows a Share Purchase Agreement to acquire an additional 43.30% stake. The acquirer will gain control of Bliss GVS Pharma.
The open offer for a substantial stake (26%) and the underlying share purchase agreement (43.30%) represent a significant change in ownership and control of Bliss GVS Pharma, which will have a high impact on the company and its shareholders.
The announcement details a significant acquisition and open offer, indicating a potential change in control and strategic direction, which is generally viewed positively for the target company's shareholders.
Bliss GVS Pharma Limited has announced that it has received a Public Announcement dated May 23, 2026, from SBI Capital Markets Limited regarding an open offer to its public shareholders. Anupam Rasayan India Limited is the proposed acquirer.
The open offer is for the acquisition of up to 2,77,26,848 equity shares, representing 26.00% of the expanded voting share capital of Bliss GVS Pharma. The offer price is ₹299.00 per equity share, with a total consideration of up to ₹829.03 crore (assuming full acceptance).
This open offer is a triggered offer, made in compliance with SEBI (Substantial Acquisition of Shares and Takeovers) Regulations, 2011, following a Share Purchase Agreement (SPA) executed on May 23, 2026. Under the SPA, the acquirer has agreed to acquire 4,58,03,024 equity shares from existing sellers, representing 43.30% of the company's equity share capital. The SPA price for these shares is also not exceeding ₹299.00 per equity share, with a total consideration of ₹13,695.10 crore.
Upon completion of the transactions contemplated in the SPA and the open offer, Anupam Rasayan India Limited will gain sole control over Bliss GVS Pharma and will become its promoter. Consequently, the current promoter and promoter group of Bliss GVS Pharma will cease to be in control and will be reclassified to the public category.
The detailed public statement (DPS) and letter of offer (LoF) are expected to be published within 5 working days of this announcement, on or before June 1, 2026.
What to do with a filing like this
Bliss GVS Pharma Limited filed this with the NSE as a statutory disclosure, categorised under substantial acquisition of shares and takeovers. It is a primary document, not a recommendation, and the desk marks it high impact, which is the band that most often changes something.
That call is the part a filing cannot make for you. On RealCase, SEBI-registered research analysts and investment advisers read announcements like this one and turn the ones that matter into actions inside their model portfolios: a change in weight, a hold, or nothing at all. You are not left working out which of the roughly 250 filings published each day needs a response. The portfolio you follow is updated when a filing actually warrants it, with the reason written down.
See the model portfoliosA plain-language summary of a public exchange filing by Bliss GVS Pharma Limited. Read the original for the full detail.